Literature DB >> 11435752

Concentration of soluble adhesion molecules (sVCAM-1, sICAM-1 and sL-selectin) in the cerebrospinal fluid and serum of patients with multiple sclerosis and systemic lupus erythematosus with central nervous involvement.

K Baraczka1, K Nékám, T Pozsonyi, L Jakab, M Szongoth, M Seszták.   

Abstract

OBJECTIVES: The aim of the present study was to investigate the role of soluble adhesion molecules in the pathogenesis of multiple sclerosis (MS) and systemic lupus erythematosus (SLE) with demyelinating syndrome.
METHODS: Paired cerebrospinal fluid (CSF) and serum samples were analysed by an ELISA method to determine the concentrations of sVCAM-1, sICAM-1 and sL-selectin. Intrathecal syntheses of the adhesion molecules were calculated.
RESULTS: Elevated serum and CSF concentrations of sVCAM-1 were present in all patient groups. Intrathecal synthesis of sVCAM-1 was present in the relapsing-remitting and secondary progressive forms of MS. Intrathecal synthesis of sICAM-1 was observed in all clinical forms of MS. MS patients with progressive forms of the disease and SLE patients were characterised by intrathecal synthesis of sL-selectin.
CONCLUSIONS: The data presented suggest that (1) blood-brain barrier damage can be assumed both in systemic disease and organ-specific disease (sVCAM-1), (2) clinical forms of MS differ from each other in respect to concentrations of adhesion molecules and (3) similar immunological events in the central nervous system of SLE patients with demyelinating syndrome and progressive forms of MS can be assumed (sL-selectin). Copyright 2001 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435752     DOI: 10.1159/000049007

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  8 in total

Review 1.  Neuroimmunopathology in a murine model of neuropsychiatric lupus.

Authors:  David A Ballok
Journal:  Brain Res Rev       Date:  2006-12-20

2.  Inhibition of C5a receptor alleviates experimental CNS lupus.

Authors:  Alexander Jacob; Bradley Hack; Tao Bai; James R Brorson; Richard J Quigg; Jessy J Alexander
Journal:  J Neuroimmunol       Date:  2010-03-05       Impact factor: 3.478

3.  Distribution of ICAM-1 immunoreactivity during aging in the human orbitofrontal cortex.

Authors:  Jose Javier Miguel-Hidalgo; Sorcha Nithuairisg; Craig Stockmeier; Grazyna Rajkowska
Journal:  Brain Behav Immun       Date:  2006-07-07       Impact factor: 7.217

4.  The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction.

Authors:  Seth G Thacker; Celine C Berthier; Deborah Mattinzoli; Maria Pia Rastaldi; Matthias Kretzler; Mariana J Kaplan
Journal:  J Immunol       Date:  2010-08-30       Impact factor: 5.422

Review 5.  Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus.

Authors:  Tony N Marion; Arnold E Postlethwaite
Journal:  Semin Immunopathol       Date:  2014-08-08       Impact factor: 9.623

6.  Switch-associated protein 70 antibodies in multiple sclerosis: possible association with disease progression.

Authors:  Recai Türkoğlu; Mehmet Gencer; Duygu Ekmekçi; Canan Ulusoy; Ece Erdağ; Elçin Sehitoğlu; Filiz Cavuş; Hazal Haytural; Melike Küçükerden; Nazlı Yalçınkaya; Selin Turan; Deniz Akbaş-Demir; Arzu Coban; Burçak Vural; Erdem Tüzün
Journal:  Med Princ Pract       Date:  2014-01-31       Impact factor: 1.927

Review 7.  Assessment of multifunctional contrast agent probes in neuroimaging: Implications of nanopharmaceutical therapeutic interventions.

Authors:  Lina H Machtoub
Journal:  J Adv Pharm Technol Res       Date:  2013-07

8.  Increase of orexin A in the peripheral blood of adolescents with Internet gaming disorder.

Authors:  Mi Ran Choi; Hyun Cho; Ji-Won Chun; Jae Hyun Yoo; Dai-Jin Kim
Journal:  J Behav Addict       Date:  2020-04-01       Impact factor: 6.756

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.